ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1CNC | CENTENE CORP | Healthcare | $34.79B | 24.28% |
2INCY | INCYTE CORP | Healthcare | $24.81B | 17.32% |
3OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 6.93% |
4IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 5.06% |
5VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 2.46% |
6PBLS | PARABILIS MEDICINES INC | Healthcare | $3.42B | 2.39% |
7DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 2.23% |
8PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.02B | 2.11% |
9HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 1.39% |
10AGL | AGILON HEALTH INC | Healthcare | $1.85B | 1.29% |
11COAG | HEMAB THERAPEUTICS HOLDINGS INC | Healthcare | $1.84B | 1.28% |
12NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 1.19% |
13ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 1.10% |
14KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.99% |
15GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.99% |
16OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.96% |
17LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.96% |
18TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.95% |
19DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.95% |
20AVLN | AVALYN PHARMA INC | Healthcare | $1.36B | 0.95% |
21PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.35B | 0.94% |
22INVA | INNOVIVA INC | Healthcare | $1.35B | 0.94% |
23KARD | KARDIGAN INC | Healthcare | $1.32B | 0.92% |
24CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.90% |
25ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.86% |
26SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 0.78% |
27MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.76% |
28JBIO | JADE BIOSCIENCES INC | Healthcare | $1.01B | 0.70% |
29CTY | CITY THERAPEUTICS INC | Healthcare | $955M | 0.67% |
30OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.64% |
31LTGO | LATIGO BIOTHERAPEUTICS INC | Healthcare | $857M | 0.60% |
32SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 0.55% |
33ATTO | ATTOVIA THERAPEUTICS INC | Healthcare | $723M | 0.50% |
34IAM | IAMBIC THERAPEUTICS INC | Healthcare | $703M | 0.49% |
35NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.49% |
36FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.48% |
37APMD | APNIMED INC | Healthcare | $692M | 0.48% |
38SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.47% |
39AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $676M | 0.47% |
40BCAX | BICARA THERAPEUTICS INC | Healthcare | $671M | 0.47% |
41ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.46% |
42CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.46% |
43CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.45% |
44SRZN | SURROZEN INC | Healthcare | $604M | 0.42% |
45TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.42% |
46IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.40% |
47AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $571M | 0.40% |
48ETRA | ELECTRA THERAPEUTICS INC | Healthcare | $557M | 0.39% |
49CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.37% |
50NGNE | NEUROGENE INC | Healthcare | $495M | 0.35% |
51MNPR | MONOPAR THERAPEUTICS | Healthcare | $488M | 0.34% |
52BLSM | BLOSSOMHILL THERAPEUTICS INC | Healthcare | $472M | 0.33% |
53ARVN | ARVINAS INC | Healthcare | $450M | 0.31% |
54AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.31% |
55MOBI | MOBIA MEDICAL INC | Healthcare | $444M | 0.31% |
56PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.30% |
57TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.29% |
58MASS | 908 DEVICES INC | Healthcare | $407M | 0.28% |
59LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.27% |
60CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $384M | 0.27% |
61FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.27% |
62MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.23% |
63BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.22% |
64EVMN | EVOMMUNE INC | Healthcare | $291M | 0.20% |
65QTTB | Q32 BIO INC | Healthcare | $264M | 0.18% |
66BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.18% |
67ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.17% |
68SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.17% |
69UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.16% |
70RXST | RXSIGHT INC | Healthcare | $226M | 0.16% |
71DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.16% |
72AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.14% |
73TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.14% |
74KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.14% |
75RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.14% |
76ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.13% |
77ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.13% |
78STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.11% |
79INGN | INOGEN INC | Healthcare | $146M | 0.10% |
80RNA | ATRIUM THERAPEUTICS INC | Healthcare | $128M | 0.09% |
81CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.09% |
82SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.09% |
83IMUX | IMMUNIC INC | Healthcare | $106M | 0.07% |
84RTSN | RETENSION PHARMACEUTICALS INC | Healthcare | $97M | 0.07% |
85JYNT | JOINT CORP | Healthcare | $92M | 0.06% |
86RLYB | RALLYBIO CORP | Healthcare | $84M | 0.06% |
87VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.06% |
88GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.05% |
89XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.04% |
90POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.04% |
91COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.04% |
92YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.04% |
93ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.04% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $143.25B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 70% toward Large, 36% toward Growth. +3% unclassified (11 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T052248 rates=20261113T052248
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 19.2% | -5.2% |
| 3 yearsp.a. | 19.1% | 2.1% |
| 5 yearsp.a. | -0.0% | -8.6% |
| 10 yearsp.a. | 4.7% | -6.0% |
| Since inceptionp.a. | 9.4% | -2.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 21.9% | -4.9% |
| 2025 | 36.7% | 16.5% |
| 2024 | -14.4% | -13.7% |
| 2023 | 15.3% | 21.0% |
| 2022 | -36.7% | -36.7% |
| 2021 | -32.0% | -47.0% |
| 2020 | 52.7% | 42.2% |
| 2019 | 22.8% | -0.0% |
| 2018 | -8.5% | -12.3% |
| 2017 | 35.9% | 17.3% |
| 2016 | -14.3% | -8.7% |
| 2015 | -2.0% | -6.6% |
| 2014 | 23.8% | -1.5% |
| 2013 | 43.7% | -0.9% |
| 2012 | 14.3% | -2.9% |
| 2011 | 7.3% | -5.5% |
| 2010 | 22.5% | 17.3% |
| 2009 | 5.9% | -27.4% |
| 2008 | -27.0% | -2.4% |
| 2007 | 1.8% | -8.0% |
| 2006 | 19.5% | 9.6% |
| 2005 | 16.8% | 4.8% |
| 2004 | 14.0% | -1.2% |
| 2003 | 59.8% | 29.8% |
| 2002 | -32.4% | -19.3% |
| 2001 | -12.3% | -23.2% |
| 2000 | 85.2% | -2.1% |
| 1999 | 51.8% | 57.2% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare NetDebtPrice Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a NetDebtPrice signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.